Heritage Investors Management Corp Raises Stock Holdings in IQVIA Holdings Inc. $IQV

Heritage Investors Management Corp raised its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 7.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 109,388 shares of the medical research company’s stock after purchasing an additional 7,239 shares during the quarter. Heritage Investors Management Corp’s holdings in IQVIA were worth $18,655,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in IQV. Ameliora Wealth Management Ltd. purchased a new stake in shares of IQVIA during the 4th quarter valued at about $25,000. International Assets Investment Management LLC bought a new position in shares of IQVIA in the 4th quarter valued at about $27,000. Gilpin Wealth Management LLC purchased a new position in IQVIA in the fourth quarter worth about $27,000. CrossGen Wealth LLC bought a new stake in IQVIA during the fourth quarter worth approximately $28,000. Finally, Measured Wealth Private Client Group LLC purchased a new stake in IQVIA during the third quarter valued at approximately $30,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Robert W. Baird raised their price target on IQVIA from $230.00 to $249.00 and gave the stock an “outperform” rating in a research report on Wednesday. Evercore reissued an “outperform” rating and issued a $185.00 target price on shares of IQVIA in a research note on Wednesday, April 8th. Morgan Stanley restated an “equal weight” rating and issued a $200.00 target price (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. TD Cowen raised shares of IQVIA from a “hold” rating to a “buy” rating and lifted their price target for the stock from $174.00 to $213.00 in a research note on Monday, March 9th. Finally, Weiss Ratings downgraded shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, May 4th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $222.00.

IQVIA Price Performance

Shares of IQV stock opened at $206.38 on Friday. The stock has a 50 day moving average price of $176.33 and a 200 day moving average price of $189.18. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $247.04. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. The firm has a market capitalization of $34.44 billion, a P/E ratio of 25.57, a P/E/G ratio of 1.74 and a beta of 1.20.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The company had revenue of $4.15 billion for the quarter, compared to the consensus estimate of $4.10 billion. During the same quarter in the prior year, the company posted $2.70 EPS. IQVIA’s quarterly revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 11.6 earnings per share for the current year.

IQVIA declared that its board has approved a stock buyback program on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board of directors believes its stock is undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.